by Megan Pullins | Apr 1, 2019 | Primary Care
Life-saving Potential As a trusted health professional, your words on the topic can greatly impact perspectives on being an organ donor, help see through myths, and, at the very least, help people remember that donating is important. A single organ donor can save up...
by PEPID Newsroom | Mar 29, 2019 | Alerts
[elfsight_social_share_buttons id=”3″] Jatenzo, (testosterone undecanoate) has been given the FDA greenlight to be used as an oral capsule treatment for men with certain forms of hypogonadism. Jatenzo is the first treatment option for men with certain...
by PEPID Newsroom | Mar 28, 2019 | Alerts
Influenza activity, particularly caused by the A(H3N2) virus, remains elevated across the US. The CDC has released a health advisory, reminding clinicians to keep influenza top of mind when diagnosing patients with respiratory illness. The report contains several...
by Anna Tan | Mar 26, 2019 | Primary Care
1 in 4 Adults are Still Unaware That They are Living with Diabetes. For how seriously debilitating and life-altering diabetes can be for about 30.3 million diagnosed Americans, the American Diabetes Association (ADA) estimates that nearly 1 in 4 adults, or 7.2 million...
by PEPID Newsroom | Mar 25, 2019 | Alerts
Multiple states across the U.S. have reported hepatitis A outbreaks among people who use drugs and people experiencing homelessness. Since the initial awareness of the outbreak in 2016, there have been more than 15,000 cases with 57% in need of hospitalizations, and...
by PEPID Newsroom | Mar 21, 2019 | Alerts
The FDA approved the Optimizer Smart system for patients with chronic, moderate-to-severe heart failure who are not suited for treatment with other heart failure devices such as cardiac re-synchronization therapy to restore a normal heartbeat timing pattern. The...
by Anna Tan | Mar 20, 2019 | Alerts
FDA Approves Spravato (esketamine) nasal spray to treat treatment-resistant depression in adults, but is only available at certified doctor’s offices and clinics. Treatment-resistant patients are adults with major depressive disorder, who have tried a minimum of two...
by PEPID Newsroom | Mar 19, 2019 | Alerts
Tuesday, March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use to treat post-partum depression (PPD) in adult women. No other drug before now has been approved to specifically treat PPD. Zulresso will be available through Risk Evaluation...
by PEPID Newsroom | Mar 14, 2019 | Alerts
The Food and Drug Administration (FDA) has allowed marketing of ClearMate to treat patients suffering from carbon monoxide poisoning in emergency rooms. Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat Devices in the FDA’s...
by PEPID Newsroom | Mar 14, 2019 | Alerts
As of March 12, 2019 the U.S. FDA approved a new generic of Diovan (valsartan) for high blood pressure and heart failure to relieve the shortage from multiple recalls of generic valsartan products from several manufacturers. The approval of the new generic of Diovan...
